Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiotherapy 5Magnetic Resonance Spectroscopy 5Docetaxel 5Specimen Handling 4Gemcitabine 3Cyclophosphamide 3temsirolimus 2fludarabine 2Trastuzumab 2Temozolomide 2Sirolimus 2Radiosurgery 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Leucovorin 2Injections 2Fluorouracil 2Fluorodeoxyglucose F18 2Blood Specimen Collection 2Biopsy 2Bevacizumab 2Azacitidine 2vandetanib 1ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × diazepinomicin × CNS × Clear all
NCT00338026 2008-07-15

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

Thallion Pharmaceuticals

Phase 1 Completed
26 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Glioma, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡